Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The number of advertised biotech and pharma sector jobs remained stable through the fourth quarter of 2012, compared with the previous quarter (Nat. Biotechnol.30, 1149, 2012). There was a noticeable increase in LinkedIn's total job listings for the top 25 biotech companies (568 up from 351) and top 10 pharma companies (586 up from 468), whereas the other databases we track returned similar totals from the third quarter (Tables 1 and 2).
Table 1 Who's hiring? Advertised openings at the 25 largest biotech companies
Notable operations expansions during the quarter include Novo Nordisk's announcement of a $100-million facility to be built in Beijing. The new R&D center will be located in the Zhongguancun Life Science Park. The new facility will employ 130–200 people. WuXi AppTec opened a biologics manufacturing plant in Wuxi, China, said to be the first cGMP facility in China. WuXi had earlier formed a 50/50 joint venture with AstraZeneca's MedImmune unit to develop and commercialize MedImmune's MEDI5117 in China for autoimmune and inflammatory diseases. The monoclonal antibody (mAb) against interleukin (IL)-6 is in phase 1 testing in the US and Europe. Finally, Novartis announced it will build a $500-million facility in Singapore to support clinical and commercial production of biologics, including mAbs for cancer, autoimmune and respiratory indications. Construction will begin this quarter, with completion slated for the end of 2016.
